GCA Altium advises the shareholders of MediFox on the sale to Hg

By on Mai 10, 2018

GCA Altium acted as exclusive financial advisor to funds managed by ECM Equity Capital Management and the management shareholders of MediFox, a leading provider of software solutions to outpatient and inpatient care providers and therapy practices in Germany, on the sale to Hg, a sector expert investor, committed to helping build ambitious businesses across the technology, services and industrial technology space. This transaction underpins GCA Altium’s strong expertise in the software and healthcare sectors.

Founded in 1994, MediFox is a leading provider of software solutions to over 6,000 ambulatory care services, elderly care homes and therapists in Germany. Its software solutions support care providers with key services including resource and route planning, care and support documentation, management information systems, as well as billing, factoring and administration services. It is headquartered in Hildesheim, Germany, and employs 265 people.

MediFox has a highly attractive business model, being a well-established player with a strong position in a fragmented sector, showing a positive underlying growth trajectory whilst also having a ‚mission-critical‘ product offering, a robust financial profile and a highly competent management team.

Christian Städtler and Dr. Thorsten Schliebe, both Managing Directors at MediFox, commented: „We want to thank ECM for their strong support over the last 5 years. We look forward to leveraging Hg’s experience and track record in working with software and healthcare companies to further strengthen and expand MediFox’s position, as we continue our journey towards further growth.“

Sascha Pfeiffer, Managing Director at GCA Altium, added: „Thanks to its unique combination of innovation leadership and direct sales know-how as well as its highly scalable business model, MediFox is ideally positioned to benefit from the long-term growth in elderly care and to capture the significant growth potential from its recent expansion into the therapy segment. We are convinced that the company will continue to flourish under Hg’s ownership.“

The transaction was signed on 9 May 2018 and is subject to customary closing conditions. Terms of the transaction were not disclosed.


Mehr Informationen zu dieser und vielen anderen Transaktionen erhalten Sie HIER


Über 25.000 recherchierte Transaktionen seit 2005 - Legen Sie sich Ihre eigene Datenbank zu!


You must be logged in to post a comment Login